Treating heart failure with sildenafil

Congestive Heart Failure

Volumn 15, Issue 4, 2009, Pages 181-185

  Blum, Arnon ^a  

^a Poriya Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CARBON DIOXIDE; CYCLIC GMP; HYDRALAZINE; ISOSORBIDE DINITRATE; OXYGEN; PHOSPHODIESTERASE V; PLACEBO; PROSTACYCLIN; SILDENAFIL;

BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG FATALITY; DRUG TOLERABILITY; DYSPNEA; ENZYME INHIBITION; EXERCISE; FLUID RETENTION; FLUSHING; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FILLING; HEART OUTPUT; HUMAN; HYDROLYSIS; HYPOTENSION; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG MINUTE VOLUME; LUNG VASCULAR RESISTANCE; LUNG VENTILATION; MUSCLE PERFUSION; MUSCLE REFLEX; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REST; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; SYSTOLIC HEART FAILURE; TACHYPHYLAXIS; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION; VISUAL IMPAIRMENT;

BLOOD FLOW VELOCITY; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH; OXYGEN CONSUMPTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; QUALITY OF LIFE; REFLEX; SULFONES; SYSTOLE;

EID: 67651181080     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.00026.x     Document Type: Review

References (39)

1. Ghio S, Gavazzi A, Campana C, et.al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183-188.
2. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: Testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. 1992;19:48-54.
3. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34:1802-1806.
4. Franciosa JA, Baker BJ, Seth L. Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J. 1985;110:807-813.
5. de Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol. 1998;32:948-954.
6. Di Salvo TG, Mathier M, Semigram MJ, et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143-1153.
7. Polak JF, Holman BL, Wynne J, et al. Right ventricular ejection fraction: An indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol. 1983;2:217-224.
8. Baker BJ, Wilen MM, Boyd CM, et al. Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol. 1984;54:596-599.
9. Meluzim J, Spinarova L, Hude P, et al. Combined right ventricular systolic and diastolic dysfunction represents a strong determinant of poor prognosis in patients with symptomatic heart failure. Int J Cardiol. 2005;105:164-173.
10. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: A double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation. 2002;106:1097-1103.
11. Guazzi M, Tumminello G, Di Marco F, et.al. The effects of phosphodiesterase 5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44:2339-2348.
12. Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation. 1994;90:2780-2785.
13. Semigran MJ, Cockrill BA, Kacmarek R, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol. 1994;24:982-988.
14. Koelling TM, Kirmse M, Di Salvo TG, et.al. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol. 1998;81:1494-1497.
15. Rabe KF, Tenor H, Dent G, et al. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:L536-L543.
16. Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol. 2002;90:677-680.
17. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
18. Galie N, Ghofrani HA, Torbicki A, et al. The sildenafil use in pulmonary arterial hypertension (SUPER) study group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
19. Lepore JJ, Marco A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide. Chest. 2005;127:1647-1653.
20. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562.
21. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248.
22. Senzaki H, Smith CJ, Juang GJ, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001;15:1718-1726.
23. Karatasakis GT, Karagounis LA, Kalyvas PA, et al. Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure. Am J Cardiol. 1998;82:329-334.
24. La Vecchia L, Paccanaro M, Bonanno C, et al. Left ventricular versus biventricular dysfunction in idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:120-122.
25. Gottlieb SS. The impact of finally publishing a negative study: New conclusions about endothelin antagonists. J Card Fail. 2005;11:21-22.
26. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54.
27. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
28. Katz SD, Balidemaj K, Homma S, et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:845-851.
29. Guazzi M, Tumminello G, DiMarco F, et al. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther. 2004;76:371-378.
30. Koike A, Wasserman K, Taniguichi K, et al. Critical capillary oxygen partial pressure and lactate threshold in patients with cardiovascular disease. J Am Coll Cardiol. 1994;23:1644-1650.
31. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115:115.
32. Scott AC, Francis DP, Davies LC, et al. Contribution of skeletal muscle "eroreceptors" in the human leg to respiratory control in chronic heart failure. J Physiol. 2000;529:863-870.
33. Smith SA, Mammen PPA, Mitchell JH, et al. Role of the exercise pressor reflex in rats with dilated cardiomyopathy. Circulation. 2003;108:1126-1132.
34. Ponikowski PP, Chua TP, Francis DP, et al. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation. 2001;104:2324-2330.
35. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with congestive heart failure. Circulation. 1991;84:1589-1596.
36. Katz SD, Krum H, Hkam T, et al. Exercise induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: Role of endothelium derived nitric oxide. J Am Coll Cardiol. 1996;28:585-590.
37. Guazzi M, Casali M, Berti F, et al. Endothelium mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther. 2008;83(2):336-341.
38. Johnson RL. Gas exchange efficiency in congestive heart failure II. Circulation. 2001;103:916-918.
39. Guazzi M, Samaja M, Arena R, et.al. Long term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50(22):2136-2144.